|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,314.70 INR | -0.72% |
|
-0.49% | -13.01% |
| 03-09 | Cipla says U.S. unit to initiate recall of lanreotide injection | RE |
| 03-09 | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| Capitalization | 1,062B 11.48B 10.04B 9.07B 8.67B 15.78B 16.4B 108B 42.93B 507B 43.09B 42.18B 1,833B | P/E ratio 2026 * |
25.3x | P/E ratio 2027 * | 23.4x |
|---|---|---|---|---|---|
| Enterprise value | 967B 10.45B 9.14B 8.26B 7.9B 14.37B 14.93B 98.63B 39.09B 462B 39.23B 38.4B 1,669B | EV / Sales 2026 * |
3.41x | EV / Sales 2027 * | 3.07x |
| Free-Float |
63.97% | Yield 2026 * |
1.05% | Yield 2027 * | 1.07% |
Last Transcript: Cipla Limited
| 1 day | -0.72% | ||
| 1 week | -0.49% | ||
| Current month | -2.48% | ||
| 1 month | -1.26% | ||
| 3 months | -13.36% | ||
| 6 months | -16.51% | ||
| Current year | -13.01% |
| 1 week | 1,292.7 |  | 1,341.7 |
| 1 month | 1,292.7 | | 1,364.9 |
| Current year | 1,281.7 | | 1,539.7 |
| 1 year | 1,281.7 | | 1,673 |
| 3 years | 852 | | 1,702.05 |
| 5 years | 738.1 | | 1,702.05 |
| 10 years | 355.3 | | 1,702.05 |
| Manager | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 54 | 31/08/2016 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 15/08/2022 |
| President | - | 31/12/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 89 | 21/07/1972 | |
| Director/Board Member | 72 | 24/07/2014 | |
Umang Vohra
BRD | Director/Board Member | 54 | 31/08/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.72% | -0.49% | -10.07% | +50.76% | 11.48B | |
| -1.30% | +0.12% | +7.02% | +88.22% | 46.73B | |
| -0.14% | +9.39% | +44.46% | +178.68% | 36.39B | |
| -1.91% | +1.05% | +303.34% | +1,470.70% | 11.97B | |
| -1.20% | -0.78% | +2.58% | +92.52% | 9.86B | |
| -0.06% | +3.11% | +69.60% | +53.19% | 8.47B | |
| +0.44% | 0.00% | +36.90% | +119.05% | 7.98B | |
| +1.18% | -6.27% | +44.53% | -16.27% | 6.96B | |
| -3.80% | +2.18% | +54.48% | +422.05% | 6.62B | |
| +0.59% | +3.39% | +14.89% | +61.63% | 6.31B | |
| Average | -0.69% | +1.53% | +56.77% | +252.05% | 15.28B | |
| Weighted average by Cap. | -0.78% | +2.58% | +46.71% | +223.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 283B 3.06B 2.68B 2.42B 2.31B 4.21B 4.38B 28.91B 11.46B 135B 11.5B 11.26B 489B | 308B 3.33B 2.91B 2.63B 2.52B 4.58B 4.76B 31.43B 12.45B 147B 12.5B 12.24B 532B |
| Net income | 41.73B 451M 394M 356M 341M 620M 644M 4.26B 1.69B 19.94B 1.69B 1.66B 72.01B | 45.47B 492M 430M 388M 371M 675M 702M 4.64B 1.84B 21.72B 1.84B 1.81B 78.46B |
| Net Debt | -94.99B -1.03B -898M -811M -776M -1.41B -1.47B -9.69B -3.84B -45.38B -3.85B -3.77B -164B | -116B -1.26B -1.1B -993M -950M -1.73B -1.8B -11.86B -4.7B -55.56B -4.72B -4.62B -201B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/03/26 | 1,314.70 ₹ | -0.72% | 1,346,347 |
| 12/03/26 | 1,324.30 ₹ | -0.39% | 1,405,268 |
| 11/03/26 | 1,329.50 ₹ | -0.30% | 1,268,130 |
| 10/03/26 | 1,333.50 ₹ | +0.64% | 1,050,270 |
| 09/03/26 | 1,325.00 ₹ | +0.29% | 1,674,811 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CIPLA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition